Jefferies Financial Group assumed coverage on shares of Passage Bio (NASDAQ:ORIC) in a research note released on Tuesday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $40.00 price target on the stock.

ORIC has been the topic of a number of other research reports. Citigroup started coverage on Passage Bio in a research report on Tuesday. They issued a neutral rating and a $35.00 target price on the stock. Guggenheim started coverage on Passage Bio in a research report on Tuesday. They issued a buy rating and a $45.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Passage Bio has a consensus rating of Buy and a consensus price target of $38.60.

NASDAQ ORIC opened at $29.04 on Tuesday. Passage Bio has a one year low of $24.26 and a one year high of $34.70.

Passage Bio (NASDAQ:ORIC) last announced its earnings results on Wednesday, May 20th. The company reported ($4.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($4.20). As a group, analysts predict that Passage Bio will post -1.77 earnings per share for the current year.

In related news, Director Orbimed Advisors Llc purchased 281,250 shares of the firm’s stock in a transaction on Friday, April 24th. The stock was purchased at an average cost of $25.68 per share, for a total transaction of $7,222,500.00.

About Passage Bio

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.

Featured Article: Market Capitalization in the Stock Market

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.